What are the appropriate dosing regimens, treatment durations, and contraindications for oral and topical terbinafine (generic) in managing dermatophyte infections and onychomycosis in adults and children?

Terbinafine for Dermatophyte Infections and Onychomycosis

Oral terbinafine is the first-line treatment for dermatophyte onychomycosis, dosed at 250 mg daily for 6 weeks for fingernails and 12 weeks for toenails, with superior efficacy compared to all alternatives. 1

Oral Terbinafine Dosing

Adults - Onychomycosis

• Fingernail infections: 250 mg once daily for 6 weeks 2
• Toenail infections: 250 mg once daily for 12 weeks (can extend to 16 weeks if needed) 1, 2
• Re-evaluate 3-6 months after treatment initiation; continue if disease persists 1

Pediatric Dosing (by body weight)

For tinea capitis (griseofulvin remains the only licensed treatment in children for onychomycosis, though terbinafine is used off-label):

• <20 kg: 62.5 mg daily for 2-4 weeks 3
• 20-40 kg: 125 mg daily for 2-4 weeks 3
• >40 kg: 250 mg daily for 2-4 weeks 3

Important note: Terbinafine is highly effective against Trichophyton species but less effective against Microsporum species, particularly M. canis, due to inadequate drug concentration in hair shafts and scalp surface in prepubertal children 3.

Topical Terbinafine

• Topical formulations (1% cream/solution): Apply once or twice daily for up to 2 weeks for tinea pedis, tinea corporis/cruris, cutaneous candidiasis 4
• Newer 10% solution (MOB-015): Once daily application for 48 weeks achieved 69.9% mycological cure in onychomycosis 5
• Topical therapy alone is NOT recommended for onychomycosis—oral therapy is required for nail infections 3

Efficacy Data

Terbinafine demonstrates superior outcomes compared to alternatives:

• vs. Itraconazole: Complete cure 55% vs. 26% at 72 weeks; 5-year mycological cure 46% vs. 13% 1
• Relapse rates: 23% (terbinafine) vs. 53% (itraconazole) at 5 years 1
• Mechanism advantage: Fungicidal (not just fungistatic), with nail persistence up to 6 months post-treatment 1

Contraindications and Precautions

Absolute Contraindications

• Active or chronic liver disease 1
• History of allergic reaction to oral terbinafine (risk of anaphylaxis) 2
• Pregnancy (Category B, but treatment should be postponed) 2

Relative Contraindications/Cautions

• Nursing mothers: Terbinafine concentrates in breast milk (milk:plasma ratio 7:1); not recommended 2
• Renal impairment: Not adequately studied in creatinine clearance ≤50 mL/min 2

Mandatory Monitoring

Baseline testing required:

• Liver function tests (AST/ALT)
• Complete blood count
• Especially critical for: heavy alcohol users, hepatitis history, hematological abnormalities, and all pediatric patients 1

Discontinue immediately if:

• Liver enzyme elevation develops
• Neutrophil count ≤1,000 cells/mm³ 2
• Taste or smell disturbance occurs (can be permanent) 2
• Signs of severe skin reactions (Stevens-Johnson syndrome, TEN, DRESS) 2

Common Adverse Effects

From postmarketing surveillance (10.5% overall incidence):

• Gastrointestinal (49%): Nausea, diarrhea, taste disturbance 1
• Dermatological (23%): Rash, pruritus, urticaria 1
• Serious adverse events: 0.04% incidence 1

Critical warning: Taste disturbance, though rare, can be permanent—patients must be counseled about this risk before starting treatment 1, 2.

Drug Interactions

Terbinafine has minimal drug interactions compared to azoles 1:

• Primary concern: Inhibits CYP2D6, affecting metabolism of desipramine, certain beta-blockers, and other CYP2D6 substrates 2
• Does NOT significantly interact with most medications (unlike itraconazole/fluconazole)

Pulse Therapy Considerations

Evidence is conflicting and pulse therapy is NOT recommended as standard:

• One retrospective study suggested pulse dosing (500 mg/day for 1 week every 4 weeks) may be effective 6
• However, a 2023 randomized trial showed continuous therapy was significantly superior (76.67% vs. 26.67% cure rate) 7
• Stick with FDA-approved continuous dosing for reliable outcomes 2

Treatment Selection Algorithm

1. Confirm dermatophyte infection (KOH/culture) before starting
2. Check baseline LFTs and CBC
3. Screen for contraindications: liver disease, pregnancy, nursing
4. For onychomycosis: Use oral terbinafine 250 mg daily (6 weeks fingernails, 12 weeks toenails)
5. For tinea capitis: Use terbinafine only if Trichophyton species confirmed; use griseofulvin for Microsporum
6. For cutaneous infections: Topical terbinafine 1% for 1-2 weeks is sufficient
7. Re-evaluate at 3-6 months with repeat mycology; extend treatment if persistent

Common Pitfalls to Avoid

• Don't use topical therapy alone for nail infections—it will fail 3
• Don't forget to warn about permanent taste loss—this is a medicolegal issue 2
• Don't use in Microsporum infections without considering alternatives—terbinafine has poor efficacy 3
• Don't skip baseline liver testing—hepatotoxicity, though rare, can be severe 1
• Don't assume higher doses work better—a 2023 study showed 500 mg daily was no better than 250 mg for tinea corporis/cruris 8